BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Beyond the Glass Ceiling: Women-Led Companies Shaping Indiaâ??s Health Economy

01 March 2026 | Views | By Aarthi Janakiraman, Research Director, Advanced SciTech, Everest Group

Over the past decade, women entrepreneurs have gained strong ground in Indiaâ??s healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery. As of June 30, 2024, nearly 67,500 Department for Promotion of Industry and Internal Trade (DPIIT)-recognised startups had at least one woman director, highlighting womenâ??s growing presence in Indiaâ??s innovation ecosystem.



The past ten years have seen women entrepreneurs become more visible across India's healthcare landscape, from diagnostics and Femtech to biotech and care delivery. Women have increasingly founded healthcare companies that deal directly with operational complexity, clinical validation, and even regulatory approvals, all areas where credibility is hard-earned repeatedly and at scale.

This shift is evident in the macro indicators of India's startup economy. As the Department for Promotion of Industry and Internal Trade (DPIIT) recognised startup base expanded, a significant proportion of recognised startups have at least one-woman director, around 67,500 as of June 30, 2024, according to the Government of India report. While these numbers do not remove the need to interrogate access gaps, they at least establish a clear baseline. Women are now present at a meaningful scale across India's innovation system, including healthcare.

Healthcare participation is increasing, yet achieving scale remains the greater challenge

Healthcare operates as a slow legitimacy sector, where evidence is integral to the product. All claims require substantiation, ongoing compliance is essential, and any quality lapses may result in severe consequences. These factors lengthen product development cycles, elevate expenses, and delay returns on investment. Challenges increase with market entry. Capital allocation does not consistently match product timelines. When investors impose consumer technology speed expectations on ventures that require substantial evidence, they often inadequately fund the stages critical for building credible healthcare offerings. This misalignment can be particularly impactful for women founders, who frequently encounter heightened scrutiny regarding credibility and frequently experience an additional layer of constraint, ranging from proportional capital access to dealing with structural gaps.

Initial evidence: large-scale leadership in life sciences

India has long had an influential example of women-led leadership in a complex life-science ecosystem. Kiran Mazumdar-Shaw's Biocon still remains an often-cited example of a women-led company, which helped establish the idea that Indian biotech leadership can be women-led, science-driven, and globally credible. While Biocon's origin predates the last decade, its continuing prominence still matters for the startup ecosystem as it functions as an institutional signal to talent, investors, and partners that women-led healthcare businesses can operate at global quality and scale. This signal does not serve a symbolic purpose. In regulated industries, legitimacy accumulates over time. When markets observe effective leadership on a large scale, it lowers the perceived novelty risk associated with subsequent ventures.

Biotech: the sustained economy within healthcare entrepreneurship

At the research-intensive edge, entrepreneurship is defined less by visibility and more by endurance. Zumutor Biologics, associated with Kavitha Iyer Rodrigues, operates in immuno-oncology, an arena where programme timelines are long, evidence is expensive, and standards are unforgiving. Such ventures aren't established by rapid consumer adoption; they

scale by building scientific credibility, sustaining pipelines, and earning partnership confidence. Inclusion of such examples in the women entrepreneurship portfolio is essential as it can underline that women-led healthcare innovation in India is not limited to services and platforms; it can include deep-science programmes where the commercial outcome may take years to materialise.

Diagnostics: where trust represents the product

Diagnostics is one of the most revealing arenas for entrepreneurship as it integrates multiple demands into one operating model, from quality systems, process discipline, clinician confidence, to consumer trust. Metropolis Healthcare, under the leadership of Ameera Shah, demonstrates that achieving diagnostic scale requires operating as a high-reliability institution instead of adopting the approach of a fast-moving consumer business. Its significance for the broader women-led entrepreneurship is evident. In healthcare, credibility is a sustained operational outcome built through quality control, transparency, and repeatability, and is not a marketing outline. Women leaders who build diagnostics platforms are, in effect, building trust infrastructure for the entire healthcare system.

Femtech: transitioning from "taboo" to comprehensive women's health solutions

Historically, women's health in India experienced limited discussion, social stigma, and disjointed care. Women entrepreneurs are redefining these segments as comprehensive lifecycle healthcare markets, instead of treating them as separate instances of need.

Gytree, co-founded by Swarnima Bhattacharya, represents this movement toward building women's health ecosystems rather than single-category interventions. Laiqa Wellness, led by Monica Bindra, also reflects a related strategy of building a brand in a category where misinformation can spread quickly, and consumer confidence is fragile. Arva Health, founded by Dipalie Bajaj and Nidhi Panchmal, is positioning itself around fertility care that combines testing, navigation, and ease of clinical access. This is a strategically significant direction highlighting the move towards an integrated women's health system that creates awareness, reduces the bottlenecks in diagnosis, access, and follow-up.

Aligning Policy, Procurement and Capital

India already has public programmes; however, they can be better aligned with the realities of healthcare entrepreneurship to encourage scalable adoption and revenue. The Biotechnology Industry Research Assistance Council (BIRAC)'s Biotechnology Ignition Grant (BIG) is important for early-stage biotech and diagnostics innovators as it supports proof-of-concept, a stage where private capital is often cautious and founders require non-dilutive momentum.

Stand-Up India Mitra, which ended in 2025, provided a credit pathway for women entrepreneurs seeking bank loans for greenfield enterprises, which is very relevant to diagnostics operations, clinic-adjacent services, and manufacturing-linked ventures. MUDRA is a key microcredit mechanism for non-corporate, micro, and small enterprises that support last-mile health services and distribution models.

The strategic gap is not just awareness of schemes; it is conversion into scale, platforms must become pipelines, mentorship must convert to pilots, pilots must lead to procurement, and the system must measure outputs such as revenue, adoption, and outcomes rather than just registrations, which is consistent with NITI Aayog's Women Entrepreneurship Platform (WEP) intent and now requires a stronger healthcare-specific conversion pathways such as regulatory guidance access, procurement readiness support, and structured matchmaking for validated pilots. It is important to acknowledge that the government can open doors, but hospitals, incumbents, and investors ultimately decide who scales.

Hospitals and diagnostic chains can accelerate adoption by making partnership pathways clearer and more predictable through standardised pilot protocols, transparent evaluation criteria, and faster procurement decisions for validated solutions. Pharma and MedTech incumbents can reduce friction by offering faster decision cycles for pilots along with clearer vendor onboarding criteria.

Investors should synchronise due diligence and capital structures with the specific requirements of healthcare, as evidence-driven sectors demand patient capital, milestone-oriented funding, and evaluation informed by domain expertise. This approach enables a more precise risk model and minimises concealed penalties that may disproportionately impact women founders.

India's last decade demonstrates that women's participation in entrepreneurship has risen, and healthcare is no exception. The next phase is about establishing scale: whether women-led healthcare companies gain proportionate access to growth capital, procurement opportunities, and strategic partnerships.

Across the healthcare sector, ventures led by women consistently exhibit comparable core strategies. These organisations secure credibility early by aligning product roadmaps with evidence plans and compliance requirements. They treat quality systems as catalysts for growth rather than merely administrative tasks. Furthermore, they develop their partner ecosystem at an early stage to support strong adoption. Successful enterprises tackle challenges specific to India while upholding high standards.

The women founders, who are advancing diagnostic trust, biotech resilience, and women's healthcare solutions, are not pursuing symbolic acknowledgment. Their efforts reflect a pragmatic requirement: an ecosystem that acknowledges evidence timelines, incentivizes quality, and transforms credibility into scalable growth. If India synchronises funding, procurement, and partnership strategies with these standards, women-led healthcare organisations will not only expand but will also establish themselves as category-leading institutions.

Aarthi Janakiraman, Research Director, Advanced SciTech, Everest Group